August 6, 2013 / 6:43 AM / 4 years ago

India's Piramal Enterprises says gets U.S. nod for new drug trials

Aug 6 (Reuters) - India’s Piramal Enterprises Ltd said it has received U.S. regulatory approval to initiate phase I clinical trials for its new drug indicated for lowering lipid and diabetes treatment.

The P7435 molecule has shown significant reduction in triglycerides, blood glucose and insulin levels in pre-clinical studies, the company said in a statement on Tuesday. Its phase I trials will start soon in the United States, it said.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below